{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:45:47Z","timestamp":1783734347839,"version":"3.55.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Limited US clinical data are available on the use of aesthetic products in patients with skin of color (SOC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To compare the efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in patients with and without SOC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS AND MATERIALS<\/jats:title>\n            <jats:p>Post hoc analyses were performed on the pooled population of all 492 patients treated with 20U prabotulinumtoxinA in the 2 US single-dose Phase III glabellar line clinical studies. Patients were grouped by Fitzpatrick skin Type: IV + V + VI (with SOC) versus I + II + III (without SOC). The primary efficacy end point was the proportion of responders with a \u22651-point improvement from baseline at maximum frown on the 4-point Glabellar Line Scale. Adverse events (AEs) were also summarized.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Responder rates among patients with SOC (<jats:italic toggle=\"yes\">n<\/jats:italic> = 140) were lower than those without SOC (<jats:italic toggle=\"yes\">n<\/jats:italic> = 352), by 5.9% on average across all visits; at no time point were differences statistically significant. At Day 30, responder rates were 94.0% and 96.0%, respectively (<jats:italic toggle=\"yes\">p<\/jats:italic> = .401). Headache was the most common treatment-related AE, occurring in 12.1% and 8.2% of patients with and without SOC, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>A single dose of 20U prabotulinumtoxinA was well tolerated and similar in effectiveness in patients with and without SOC for the treatment of glabellar lines.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000002864","type":"journal-article","created":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T15:00:58Z","timestamp":1604847658000},"page":"516-521","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients With Skin of Color: Post Hoc Analyses of the US Phase III Clinical Study Data"],"prefix":"10.1097","volume":"47","author":[{"given":"Susan C.","family":"Taylor","sequence":"first","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl E.","family":"Grimes","sequence":"additional","affiliation":[{"name":"Vitiligo and Pigmentation Institute of Southern California, Los Angeles, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Joseph","sequence":"additional","affiliation":[{"name":"Clinical Testing of Beverly Hills Inc., Encino, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Jonker","sequence":"additional","affiliation":[{"name":"Medical Writing Associates, West Vancouver, British Columbia, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui L.","family":"Avelar","sequence":"additional","affiliation":[{"name":"Evolus, Inc., Newport Beach, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"210","DOI":"10.12788\/j.sder.2018.053","article-title":"Aesthetic considerations in female skin of color: what you need to know","volume":"37","author":"Henry","year":"2018","journal-title":"Semin Cutan Med Surg"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1097\/PRS.0000000000001813","article-title":"Ethnic and gender considerations in the use of facial injectables: African-American patients","volume":"136","author":"Burgess","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"R5-20250731","first-page":"31","article-title":"Aging differences in ethnic skin","volume":"9","author":"Vashi","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"R6-20250731","first-page":"616","article-title":"Myths and knowledge gaps in the aesthetic treatment of patients with skin of color","volume":"18","author":"Alexis","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"R7-20250731","first-page":"858","article-title":"Understanding the female African American facial aesthetic patient","volume":"18","author":"Alexis","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1524-4725.2009.01063.x","article-title":"A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI","volume":"35","author":"Grimes","year":"2009","journal-title":"Dermatol Surg"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/j.1524-4725.2012.02551.x","article-title":"AbobotulinumtoixnA for reduction of glabellar lines in patients with skin of color: post hoc analysis of pooled clinical trial data","volume":"38","author":"Taylor","year":"2012","journal-title":"Dermatol Surg"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/DSS.0000000000001903","article-title":"On behalf of the EV-001\/EV-002 Study Group. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical Phase III studies","volume":"45","author":"Beer","year":"2019","journal-title":"Dermatol Surg"},{"key":"R11-20250731","first-page":"413","article-title":"A multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects","volume":"40","author":"Rzany","year":"2020","journal-title":"Aesthet Surg J"},{"issue":"2 Suppl","key":"R14-20250731","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1067\/mjd.2002.120790","article-title":"Skin of color: biology, structure, function and implications for dermatologic disease","volume":"46","author":"Taylor","year":"2002","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:12:57Z","timestamp":1753999977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002864","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]}}}